Alexander Drilon, MD, is now Memorial Sloan Kettering Cancer Center’s Chief of the Early Drug Development (EDD) Service in the Division of Solid Tumor Oncology of the Department of Medicine. In this role, Dr. Drilon oversees early-phase solid tumor drug development. The EDD has an extensive portfolio of molecularly-directed, immunomodulatory and other novel systemic therapies. It includes members from the Departments of Radiation Oncology, Neurology and Pediatrics, allowing the team to engage in multimodality, primary brain tumor and adolescent-young-adult-inclusive studies.
Names & News
Dec 18, 2020